As Antimicrobial Resistance (AMR) Awareness Week comes to a close, we at Fresenius Kabi stay focused on the ongoing fight against Antimicrobial Resistance. AMR, a growing threat largely driven by antimicrobial overuse, underscores the critical role healthcare professionals have in setting responsible practices and educating patients and communities. As a dedicated AMR Industry Alliance member since 2020, and a board member since 2021, Fresenius Kabi proudly stands with the World Health Organization to advance awareness and best practices. #AMRWeek #CommittedToLife
关于我们
As a global healthcare company, Fresenius Kabi is Committed to Life. The company’s products, technologies, and services are used for the therapy and care of critically and chronically ill patients. With more than 43,000 employees and present in over 100 countries, Fresenius Kabi’s expansive product portfolio focuses on providing access to high-quality and lifesaving medicines and technologies. In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral products makes a distinct difference in patients’ nutritional status. In MedTech, the company provides vital infusion pumps, cell and gene therapy devices, disposables, and more. Fresenius Kabi is the global leader in supplying blood collection bags and devices, supporting blood banks and healthcare facilities worldwide. The company’s I.V. Generics and Fluids for infusion therapy help save millions of lives every year, in emergency medicine, surgery, oncology, and intensive care. Fresenius Kabi takes a holistic approach to healthcare and uniquely combines experience, expertise, innovation, and dedication – making a difference in the lives of almost 450 million patients annually. With Vision 2026, as part of the #FutureFresenius strategy, the company is developing, producing, and selling new products and technologies and aspires to expand its position as a leading global provider of therapies, improve patient care, generate sustainable value for stakeholders – shaping the future of healthcare. Fresenius Kabi is an operating company of the Fresenius Group, founded in 1912, along with Helios and Quirónsalud. As ONE team, the companies in the Fresenius Group are committed to providing lifesaving and life-changing healthcare solutions on a global scale. For more information, please visit www.fresenius-kabi.com. Imprint: https://www.fresenius-kabi.com/imprint
- 网站
-
https://www.fresenius-kabi.com
Fresenius Kabi的外部链接
- 所属行业
- 制药业
- 规模
- 超过 10,001 人
- 总部
- Bad Homburg，Hessen
- 类型
- 上市公司
- 领域
- I.V. Generic Drugs、Infusion Therapies、Clinical Nutrition (enteral and parenteral)、Medical Devices、Transfusion Technology Products、Biosimilars和Biopharmaceuticals
地点
-
主要
获取路线
Else-Kr?ner-Stra?e 1
DE，Hessen，Bad Homburg，61352
Fresenius Kabi员工
动态
-
Fresenius Kabi is proud to support Antimicrobial Resistance (AMR) Awareness Week. AMR is a global public health and development concern. Across all of our production sites, we work to prevent antibiotic-contaminated wastewater from being discharged into the environment. Fresenius Kabi has been an active member of the AMR Industry Alliance since 2020, and is a board member since 2021. AMR Week is a global campaign by the World Health Organization to improve awareness and understanding of AMR and encourage best practices. #AMRWeek #CommittedToLife
-
Fresenius Kabi is proud to support Antimicrobial Resistance (AMR) Awareness Week. AMR is a global public health and development concern. Providing access to antibiotics and ensuring their proper use helps to decrease the spread of bacteria and lowers the chance of antimicrobial resistance. By working together, we can combat this global threat. Fresenius Kabi has been an active member of the AMR Industry Alliance since 2020, and is a board member since 2021. AMR Week is a global campaign by the World Health Organization to improve awareness and understanding of AMR and encourage best practices. #AMRWeek #CommittedToLife
-
Antimicrobial Resistance (AMR) is a global public health and development concern. Fresenius Kabi is proud to support AMR Awareness Week, the global campaign by the World Health Organization to improve awareness and understanding of AMR and encourage best practices. Fresenius Kabi has been an active member of the AMR Industry Alliance since 2020, and is a board member since 2021. #AMRWeek #CommittedToLife
-
Today, we recognize the incredible strength and potential of preterm babies, whose early arrival reminds us of both the challenges and wonders of life. At Fresenius Kabi, we are committed to supporting their growth and health with specialized clinical nutrition and medical technologies designed for their unique needs. Behind each of our solutions lies a global network of innovation, research, and collaboration – all aimed at helping these little ones thrive. Every advancement we make is a step forward in giving premature infants the best possible start, and we are inspired by the progress we see every day. Let’s continue working together to shape a future where every preterm baby has the resources they need to grow strong. #WorldPrematurityDay #CommittedToLife
-
-
Malnutrition is a serious threat that impacts patients' recovery, quality of life, and treatment outcomes. Yet, day by day, healthcare professionals around the world work tirelessly to turn the tide. We would like to say “thank you” to all healthcare professionals who work passionately to deliver life-sustaining treatments, helping to ensure that patients have a solid foundation for health, with nutrition being a vital part of it. Every day, your work makes a real difference in the lives of patients, supporting their treatment and recovery. ?? At Fresenius Kabi, we are committed to supporting your passion in the fight against malnutrition. Together we make a real difference! ?? We also support research and advancements in this field through our international programs like the JUMPstart Clinical Nutrition Program, special grants such as the LAM Research Grant and the ESICM-Fresenius Kabi Clinical Nutrition Research Award, as well as global initiatives like United for Clinical Nutrition (UFCN). #ESPENMAW2024 #NutritionMatters #MedicalNutrition #CommittedToLife
Thank you to all healthcare professionals fighting malnutrition
-
So proud that Fresenius Kabi has received the 2024 Novaplus Program Excellence Award from Vizient, recognizing our commitment to superior service, reliability, and integrity. This award is truly a testament to the dedication of our teams across the U.S. and globally. Over the past year, we delivered high-quality pharmaceutical solutions that support Vizient members and their patients.?Special thanks to our incredible teams at Fresenius Kabi USA for achieving this milestone. Together, we are #CommittedToLife. #FreseniusKabi #FutureFresenius #Vizient #Novaplus?
Fresenius Kabi is pleased to announce we’ve received the 2024 Novaplus Program Excellence Award from?Vizient, Inc! This recognition honors our team's exceptional service, reliability, ethics, and integrity in partnership with Vizient and its members. In the past year, our efforts have ensured that more essential medications reached Vizient providers, directly supporting patient care. Our dedication to maintaining a reliable supply of critical drugs highlights Fresenius Kabi’s pivotal role in the healthcare network. Congratulations to our team for their indispensable support and continued excellence, making a profound impact on public health. Read the news release: https://lnkd.in/e2ZEnpT5 #VizientAwards?#Pharma #TeamFresenius #CommittedToLife
-
-
We now have four biosimilars approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), expanding access to high-quality treatments for patients across the globe. Fresenius Kabi’s growing pipeline of autoimmune and oncology biosimilars also has several molecules in early and late-stage development. ? Wondering how biosimilars can make a difference? Biosimilars are paving the way for a more accessible, affordable healthcare future by: ?? Lowering costs for patients and healthcare systems ?? Expanding access to treatments ?? Increasing high-quality treatment options for patients and healthcare providers Biosimilars enable more patients to gain access to the care they need! #GlobalBiosimilarsWeek #Biosimilars #FutureFresenius #CommittedToLife
Biosimilars - Did you know?
-
Altogether, up to 33 million patients struggle with malnutrition every year, at an annual cost of €170 billion in Europe alone. It affects one in three patients in care homes and nearly a quarter of those in hospitals. This Malnutrition Awareness Week is a vivid reminder of the millions who face related health challenges and the critical importance of nutrition for recovery and resilience overall. And malnutrition is not limited to any one region or age group. It potentially affects everyone. Behind these numbers are individuals whose recovery, dignity, and quality of life depend on accessible nutritional support. When people don’t receive the nutrients they need, healing can slow down, leading to longer recovery times and even setbacks. This doesn't just impact individuals – it places a significant strain on healthcare systems. At Fresenius Kabi, we are committed to play a decisive role in making state-of-the-art clinical nutrition accessible. And clinical nutrition is truly driven by continuous innovation that improves the treatment outcome of critically and chronically ill patients. It’s all about placing patients at the heart of care and giving them the chance to regain strength, resilience, and independence. #FreseniusKabi #FutureFresenius #CommittedToLife #MalnutritionAwarenessWeek
-
We proceed on our #Biopharma platform in line with #FutureFresenius:?mAbxience, a Fresenius Kabi majority-owned group, and Egis Pharmaceuticals PLC have entered a strategic commercialization agreement for two biosimilar candidates in key Central and Eastern European markets. This is great news and underlines our shared commitment to?making high-quality, life-saving treatments accessible in global healthcare. #CommittedToLife
Today, mAbxience and Egis Pharmaceuticals PLC announced a strategic commercialization agreement for two biosimilar candidates in Central and Eastern Europe. As majority stakeholder, mAbxience is an important pillar of Fresenius Kabi’s growth agenda in the biopharma segment. Together with our partners, we are working towards a shared goal: driving accessibility of life-saving biological treatments for patients worldwide. #FreseniusKabi #FutureFresenius #CommittedToLife